DBV Technologies

195 articles about DBV Technologies

• Professor Hugh Sampson Joins Scientific Advisory Board of DBV Technologies

  5/31/2012

• DBV Technologies: First Quarter 2012 Topline, Scientific Activity and Upcoming Clinical Data

  5/15/2012

• DBV Technologies Proudly Welcomes Mr. David Schilansky as its New Chief Financial Officer

  12/6/2011

• DBV Technologies Demonstrates Ability of VIASKIN® to Administer Allergen via Intact Skin by Targeting Dendritic Cells for Safe Treatment of Allergic Disease

  5/17/2011

• DBV Technologies Elects George Horner as Non-executive Chairman of the Board of Directors to Advance the Clinical Development of VIASKIN® Peanut, the World’s First Epicutaneous Skin Patch for Desensitization of Peanut Allergy

  1/18/2011

• DBV Technologies Adds $25.5 Million in Series C

  1/5/2011

• DBV Technologies Granted US Patents for Allergen Delivery System VIASKIN(R)

  9/24/2010

• DBV Technologies Release: VIASKIN(R) PEANUT Selected for U.S. Consortium of Food Allergy Research's Peanut Allergy Desensitization Trial Funded by the National Institutes of Health (NIH)

  9/1/2010

• DBV Technologies Receives IND Clearance from FDA to Begin Clinical Trial in Peanut Allergy

  7/6/2010

• DBV Technologies Expands Scientific Advisory Board With Appointment Of Leading Paediatric Allergy Specialist

  12/18/2009

• DBV Technologies Expands Scientific Advisory Board with Appointment of Leading Food and Paediatric Allergy Specialists

  10/19/2009

• DBV Technologies and Bioprojet Enter Into Distribution Agreement For Diallertest(R) Milk

  10/12/2009

• DBV Technologies Signs Strategic Agreement with Assistance Publique-Hôpitaux de Paris Office of Technology Transfer and Industrial Partnerships

  4/15/2009

• DBV Technologies Expands Board of Directors

  2/19/2009

• Biopharmaceutical Company DBV Technologies Expands Management Team and Moves to New Facilities; More Jobs

  9/17/2007